SK 1404Alternative Names: SK-1404
Latest Information Update: 26 Oct 2016
At a glance
- Originator Sanwa Kagaku Kenkyusho
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Nocturia
Most Recent Events
- 01 Aug 2016 Sanwa Kagaku Kenkyusho completes a phase I trial in Nocturia (In volunteers) in United Kingdom (NCT02878096)
- 01 Jul 2016 Phase-I clinical trials in Nocturia (In volunteers) in United Kingdom (PO) (NCT02878096)